Kornimate/medical-research-clean huggingface dataset:
study evaluating desvenlafaxine succinate sustained release in outpatients with major depressive disorder

Conditions: Depressive Disorder, Major

Summary: this is a multicenter study to assess the health and well-being in subjects who are outpatients with major depressive disorder that take desvenlafaxine succinate sustained release (dvs sr) or placebo for 12 weeks.


Eligibility criteria:
inclusion criteria: * outpatient men and women, between the ages of 18 to 75 years, fluent in both written and spoken english. * employed for 20 hours or more for a minimum of 1 month prior to baseline. * primary diagnosis of major depressive disorder with symptoms for at least 30 days prior to baseline. exclusion criteria: * treatment with desvenlafaxine succinate sustained release at any time in the past and/or venlafaxine (effexor or effexor xr) 1 year prior to baseline. * treatment-resistant defined as any of the following failed treatments in the past 3 years: 3 or more previous adequate trials of \>=2 classes of antidepressant medication, electroconvulsive therapy, or psychotherapy (2 adequate trials). * current (within 12 months prior to the screening visit) psychoactive substance abuse or dependence (including alcohol), manic episode, posttraumatic stress disorder, obsessive-compulsive disorder, or a lifetime diagnosis of bipolar or psychotic disorder. * clinically important abnormalities on physical examination, electrocardiogram (ecg), or laboratory evaluations.

Keywords: major depressive disorder
non-operative radiation management of adenocarcinoma of the lower rectum

Conditions: Cancer of Rectum; Cancer of the Rectum; Neoplasm, Rectum; Rectal Cancer; Rectum Cancer; Rectum Neoplasms; Adenocarcinoma of the Rectum

Summary: the purpose of this research study is to look at how tumors responds to a short course of radiation (5 days) followed by 8 cycles of chemotherapy.


Eligibility criteria:
inclusion criteria: * diagnosis of biopsy proven stage i-iiib (ct1-3, n0-1, m0) adenocarcinoma of the rectum; staging must also be based on multidisciplinary evaluation including mri and/or endorectal ultrasound * tumor ≤ 12 cm from anal verge as determined by mri or endoscopy a * ecog performance status 0-2 * at least 18 years of age * adequate bone marrow function defined as: * anc \> 1,500 cells/mm3 * hgb \> 8 g/dl * platelets \>100,000 cells/mm3 * women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. * able to understand and willing to sign an irb-approved written informed consent document. exclusion criteria: * no clinically detectable (mr, endoscopy or dre) tumor present * prior radiation therapy, chemotherapy or extirpative surgery for rectal cancer. * any evidence of disease from another malignancy or history of other malignancy ≤ 3 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix). patients with history of prostate cancer treated without radiotherapy and no evidence of disease are eligible. * currently receiving any investigational agents. * a history of allergic reaction attributed to compounds of similar chemical or biologic composition to 5fu, oxaliplatin, or leucovorin. * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * pregnant and/or breastfeeding. women of childbearing potential must have a negative serum pregnancy test within 14 days of study entry. * known hiv-positivity and on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with the study drugs. in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
flexibility deficit in chronic ankle instability

Conditions: Chronic Ankle Instability

Summary: chronic ankle instability could be associated with some proximal deficits as in hip and knee regions. these deficits include alternations in motor neurons pools excitability, muscle strength, kinematics and kinetics. this study add muscle inflexibility to the preciouse literature.

background: influence of a localized injury in a distal joint on the function of proximal muscles is an important consideration in assessment and treatment of musculoskeletal injuries. up to the investigator's knowledge, there is no study assess flexibility changes in cai. objectives: the objective of this study is to investigate hamstring flexibility in cai. material and methods: the study conducted on 42 subjects with unilateral cai and controls had measure of hamstring flexibility using digital inclinometer during passive knee extension test .results: revealed statistical and clinical significant difference between non-injured control group and cai group with decreased hamstring flexibility in the later. conclusion: cai subjects have proximal muscular affection include hamstring tightness which may alter sacroiliac joint stability and subsequently back pain.

Eligibility criteria:
inclusion criteria: * the control group was self-reported to be healthy * had no ankle injury history * matched with cai patients in gender, dominance side and simulated injured side * cai group had a self-report of a past history of unilateral ankle inversion injury since at least more than 1 year before the study onset which required a period of protected weight bearing and/or immobilization at least one day * patient reported a tendency for the ankle to give way and/or recurrent ankle sprain * perceives that the ankle was chronically weaker, more painful and/or less functional than the other ankle or than before first exclusion criteria: * had a history of lower extremity injury * surgery or fracture * history of low back dysfunction that required medical or surgical intervention within the last year, current participation in formal or informal rehabilitation * history of hamstring strain * bilateral ankle sprain injury * ankle injury within 3 months of participation * history of ankle fracture and any neuromuscluskeletal disease could affect the condition.

Keywords: chronic ankle instability hamstring flexibility
comparison of concomitant cisplatin versus carboplatin and 5-fluorouracil with radiotherapy for locally advanced head and neck squamous cell carcinoma

Conditions: Head and Neck Squamous Cell Carcinoma

Summary: concomitant chemoradiotherapy improves overall survival in patients with locally advanced head and neck squamous cell carcinoma (la-hnscc) compared to radiotherapy alone. cisplatin 100 mg/m2 at day 1, 22 and 43 is widely used but results in considerable acute and late toxicity. three cycles of carboplatin plus 5-fluorouracil (5-fu) is an accepted alternative but both chemotherapy regimens have not been compared prospectively. the aim of this study is to compare tolerability, efficacy, toxicity and quality of life in patients with la-hnscc treated with concomitant cisplatin and carboplatin plus 5-fu.

this is a retrospective comparison of patients with la-hnscc treated with chemoradiotherapy at 2 tertiary care centers in the netherlands (umcg and vumc), where one center routinely gives carboplatin plus 5fu (umcg) and the other center (vumc) uses high dose cisplatin as standard of care.

Eligibility criteria:
inclusion criteria: * stage iii-iv la-hnscc of hypopharynx, oropharynx, larynx, oral cavity * primary treatment with concomitant chemoradiotherapy consisting of three-weekly cisplatin or carboplatin plus 5-fu * age ≤ 70 years * no previous treatment for head and neck cancer * no distant metastases exclusion criteria: * previous treatment for head and neck cancer * distant metastases

Keywords: head and neck squamous cell carcinoma cisplatin carboplatin 5-fluorouracil
association between retinal microvasculature and optic disc alterations in non-pathological high myopia with octa

Conditions: Myopia

Summary: non-pathological high myopia patients and controls undergoing a comprehensive ophthalmologic examination are included. the optical coherence tomography angiography (octa) software automatically segments these full-thickness retinal scans into the superficial and deep inner retinal vascular plexuses, outer retina, and choriocapillaris (cc). the vascular density in the superficial and deep retinal vascular zones is calculated automatically by the software, and the foveal avascular zone (faz) and foveal density (fd) are also automatically determined. choroidal thickness is calculated manually by two retinal specialists, and the average value was used.

non-pathological high myopia patients and controls undergoing a comprehensive ophthalmologic examination, including measurements of best-corrected visual acuity, refractive error; intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination and octa imaging are included. the best-corrected visual acuity is convert into the logarithm of minimal angle resolution. the octa images are independently graded and assessed by two retinal specialists. the software automatically segmented these full-thickness retinal scans into the superficial and deep inner retinal vascular plexuses, outer retina, and choriocapillaris (cc). the vascular density in the superficial and deep retinal vascular zones is calculated automatically by the software, and the foveal avascular zone (faz) and foveal density (fd) are also automatically determined. choroidal thickness is calculated manually by two retinal specialists, and the average value was used. right eye of each participant is included in the study. if the right eye shows any exclusion criteria, then the left eye is selected for enrollment. eyes with an al longer than 26 mm are included in the hm group. the classification of myopic maculopathy is applied in identification of fundus alterations. patients with category 0 (no myopic retinopathy lesions) and category 1 (tessellated fundus) are included in the study.

Eligibility criteria:
inclusion criteria: * patients with category 0 (no myopic retinopathy lesions) * patients with category 1 (tessellated fundus) exclusion criteria: * poor image quality (signal strength index (ssi) \<60) due to unstable fixation * iop \>21 mm hg; logmar \> 0.1 * pre-existing ophthalmic pathologies * prior ocular surgery * systemic chronic disease which can cause retinopathy * such as diabetes mellitus, hypertension etc.
predicting mortality in patients with return of spontaneous circulation after cardiac arrest

Conditions: Post-Resuscitation Syndrome; Critical Illness; Cardiac Arrest; Hypoxic-Ischemic Encephalopathy; Coma

Summary: this observational study aims to identify early predictors of in-hospital mortality in adult patients who achieved return of spontaneous circulation (rosc) after cardiac arrest. the study prospectively enrolls patients admitted to the intensive care unit at a tertiary care hospital in turkey. various clinical, biochemical, and resuscitation-related parameters will be recorded within the first 24 hours of icu admission. the primary goal is to determine which factors are most strongly associated with mortality within 30 days. the findings are expected to improve clinical decision-making and risk stratification in the management of post-cardiac arrest patients.

this is a prospective observational study conducted in the intensive care unit (icu) of gazi yaşargil training and research hospital, turkey. the study aims to identify independent predictors of in-hospital mortality in patients who achieve return of spontaneous circulation (rosc) after cardiac arrest. adult patients (age ≥ 18 years) who were resuscitated after cardiac arrest and admitted to the icu are consecutively included. data are collected prospectively on admission and within the first 24 hours, including demographic characteristics, cause and type of arrest, time to rosc, initial rhythm, hemodynamic parameters, neurological status, lactate, ph, base excess, biomarkers, and therapeutic interventions. primary outcome is 30-day in-hospital mortality. secondary outcomes include neurological outcome at discharge and icu length of stay. patients are followed up until hospital discharge or death. the data will be analyzed using multivariate logistic regression to identify independent risk factors for mortality. the study was approved by the institutional ethics committee, and no intervention beyond routine care is performed. results are expected to improve clinical prognostication and guide decision-making for patients with rosc after cardiac arrest.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * achieved return of spontaneous circulation (rosc) after cardiac arrest * admitted to the intensive care unit (icu) * informed consent obtained from patient or legal representative (if applicable) exclusion criteria: * age \< 18 years * known pregnancy * brain death at the time of icu admission * patients with missing key clinical or laboratory data * declined participation or legal refusal

Keywords: cardiac arrest rosc in-hospital mortality icu post-resuscitation care neurological outcome
effectiveness of rifabutin in the treatment of mycobacterium avium complex

Conditions: Nontuberculous Mycobacterial Infections

Summary: treatment of adults with chronic mycobacterium avium-intracellulare complex lung infections who have failed or are intolerant of rifampin. rifabutin may be a reasonable alternative agent in patients who fail rifampin or or intolerant of rifampin.

rifabutin dosage 150-300 mg daily( depending upon age, and clinical conditions) in ntm patients who fail treatment with rifampin.

Eligibility criteria:
inclusion criteria: * adults age 18 and older with positive acid-fast bacilli smears and cultures for drug-resistant mycobacteria exclusion criteria: * children less than 18 years of age * pregnancy * low platelet count, except with very serious disease

Keywords: mac and ntm
psychotrauma prevention algorithm : randomized, controlled pilot study

Conditions: Psychological Trauma

Summary: a randomized pilot study which proposes to patients having suffered a traumatic event to have either only the standard care or the standard care associated with adaptated psychotrauma watch and prevention system.


Eligibility criteria:
inclusion criteria: * person who the vital prognosis has or could have been committed or having felt a threat to his physical and/or psychological integrity * after a potentially traumatic event dating from a minimum of 72 hours to a maximum of 1 week * for which the cump or the psychotrauma regulation platform has been requested * having lived or being a direct witness of the event * knowing how to read and write * affiliate or beneficiary of a social security scheme * having signed a consent non-inclusion criteria: * guardianship or curatorship * unable to receive phone calls * unable to go to a place for consultation
community web health portal for diabetes prevention

Conditions: Obesity; Health Knowledge

Summary: this study supports the development of a diabetes prevention and control community web portal. the portal will feature an innovative personalized impediment profiling tool and reward program. the program, "nutrition navigation on-line edge," or nnoledge, will be used by community consortiums for weight loss and diabetic health interventions within their communities. the specific aims are: 1. recruitment of local community organizations to participate as a community health consortium 2. development of a comprehensive community health web portal consisting of a web portal, impediment profiler, community toolbox, and rewards system 3. final evaluation of the system with regard to participants' attitudes and perceptions of using nnoledge as a tool for weight control and diabetes prevention to determine feasibility.


Eligibility criteria:
inclusion criteria: * can read and write english exclusion criteria: * cannot read and write engish
ci(r)ca : coumadin interaction with rofecoxib, celecoxib and acetaminophen

Conditions: Antiphospholipid Antibody Syndrome

Summary: coumadin drug-drug interactions (ddi) are frequent. patients in permanent use of coumadin are advised to avoid traditional nonsteroidal antiinflammatory drugs to avoid risk of bleeding. new selctive cyclooxygesase 2 inhibitors arisen as potential option for treating pain and inflamation in these patients once interactions with coumadin are supposed to be lower. the ci(r)ca study was made to evaluate in a prospective fashion the occurrence of ddi with new cyclooxygenase antiinflammatory drugs and coumadin when compared to acetaminophen and placebo.

the ci(r)ca study included patient diagnosed with antiphospholipid syndrome in permanent use of coumadin. eligible patients were invited to use in a prospective cross-over mode two weeks of celecoxib, rofecoxib, acetaminophen and placebo with two weeks of wash out between drugs. their international normalized ratio (inr) were measured before and during the use of each study drug. the interaction with coumadin was evaluated according to increases or decreases on the inr after each medication.

Eligibility criteria:
inclusion criteria: * paps on contious stable dose of coumadin * 18 years old or older * younger than 65 yo * signed informed consent. exclusion criteria: * renal failure * heart failure * symptomatic gastritis or peptic ulcer * elevated liver enzymes (\>3 fold) * platelet count \< 100,000.

Keywords: coumadin celecoxib rofecoxib acetaminophen antiphospholipid syndrome and inr
effect of per-cutaneous nephrosotomy drainage on radioisotope imaging of hydronephrotic kidneys

Conditions: Hydronephrosis

Summary: hydronephrosis describes a condition of urine-filled dilation of the collecting system. normally, urine flows through the urinary tract with minimal or low pressure. if the build-up of excess fluid in the urinary collecting system continues, there will be an increase in pressure and atrophy of renal cortex. if hydronephrosis is left untreated for a long time, renal damage with permanent loss of function occurs


Eligibility criteria:
inclusion criteria: * 1) patients for whom a percutaneous nephrostomy is indicated provided that the hydronephrosis is advanced ( parenchymal thickness not more than 5 mm ) 2) patients for whom a nephrectomy is planned for a seemingly poorly functioning kidney along with either exclusion criteria: 1. target kidney is the only functioning or better functioning kidney or otherwise substantially contributing to the total renal function, so nephrectomy is not likely. 2. emergency cases where the general condition of the patient cannot withstand the logistics of undergoing a radioisotope study eg 3. malignancy in the target kidney 4. patients unlikely to undergo a nephrectomy
telemedicine in age-related macular degeneration

Conditions: Age Related Macular Degeneration

Summary: this study seeks to evaluate a system for the automated early detection of age-related macular degeneration (amd). amd is a condition in which there is breakdown of the macula of the eye, the part of the retina that is responsible for sharp, central vision. we will take pictures of subjects' eyes using an automated camera. these photographs will be securely transmitted and and then analyzed by a computer program which has been developed in other studies. the outcome of the computer program analysis will be compared with human analysis of these same pictures. if the computer analysis is has good enough accuracy, then this computer system could be used for wide-scale screening for amd.

ipredict,an ai and telemedicine based software which used individual's color fundus image for early diagnosis of amd and predict if an individual is at risk of progression to late amd. ipredict platform integrates the server-side programs (the image analysis and deep-learning modules for amd severity screening and prediction) and local remote computer/mobile devices (for collecting patient data and images). drs plus camera will be used in the doctor's office. the remote devices will upload images and data to the server to analyze and screen amd automatically. the telemedicine platform has been developed for web-based platform. the automatic analysis will be performed on the server, and a report will be sent to the patient/remote devices with an individual's amd stage as referable or non-referable amd, and a risk prediction score of developing late amd (within a minute), and further recommendations to visit a nearby ophthalmologist.

Eligibility criteria:
inclusion criteria: 1. subjects will be recruited if willing and able to comply with clinic visit and study-related procedures, and provide signed informed consent 2. gender of subjects: both males and females will be invited to participate. 3. age of subjects: patients will be over 50 years and older exclusion criteria: 1. unable to provide informed consent. 2. other retinal degenerations and retinal vascular diseases such as diabetic retinopathy or macular edema, prior retinal surgery.
the effects of wheat sprouts supplements on the key health indicators of the patients with breast cancer after chemotherapy

Conditions: Nutritional Status, Immune Function, Quality of Life Uring the Progress of Chemotherapy

Summary: to explore the effects of wheat sprouts supplements on the key health indicators of the patients with breast cancer after chemotherapy, maiji tablets, a wheat sprouts supplement, were used to treat 26 patients during the progress of chemotherapy and nutritional status, immune function, quality of life were measured and evaluated. through data analysis, we found that maiji tablets may improve the symptoms of appetite loss, nausea and vomiting, and fatigue in patients with breast cancer during chemotherapy. meanwhile it may help patients maintain weight, keep appetite and improve the food intake.


Eligibility criteria:
inclusion criteria: - patients diagnosed with breast cancer, receiving chemotherapy for the first time exclusion criteria: - patients with severe liver or kidney disease or other infectious diseases